Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies
“This financing not only strengthens our ability to advance CBX‑250 through clinical development but also accelerates our mission to bring next‑generation TCR‑mimetic immunotherapies to patients who urgently need new options,” said Briggs Morrison, M.D., Chief Executive Officer of Crossbow Therapeutics. “We greatly appreciate our investors for sharing our conviction in the transformative potential of our T‑Bolt™ platform. We look forward to efficiently expanding our pipeline to address cancers that remain beyond the reach of today’s therapies.”
Share:
More News
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two